Impactherapeutics in Andover, OH - Community/Behavioral Health

Impactherapeutics is a mental health clinic (Community/behavioral Health) in Andover, Ohio. The current practice location for Impactherapeutics is 150 W Main St, Andover, Ohio. For appointments, you can reach them via phone at (440) 895-7356. The mailing address for Impactherapeutics is 150 W Main St, Andover, Ohio and phone number is () -.

Impactherapeutics is licensed to practice in * (Not Available) (license number ) and its NPI number is 1306613823. This medical practice does not participate in medicare program and thus may not accept your medicare insurance. You may check if they accept your insurance at (440) 895-7356.

Contact Information

	Impactherapeutics
	150 W Main St Andover OH 44003-9318
	(440) 895-7356
	Not Available

Mental Health Clinic Profile

Full Name	Impactherapeutics
Speciality	Community/behavioral Health
Location	150 W Main St, Andover, Ohio
Authorized Official Name and Position	Ashley Bair (CHIEF OPERATING OFFICER)
Authorized Official Contact	4408957356
Accepts Medicare Insurance	This clinic does not participate in Medicare Program.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Impactherapeutics 150 W Main St Andover OH 44003-9318 Ph: () -	Impactherapeutics 150 W Main St Andover OH 44003-9318 Ph: (440) 895-7356

NPI Details:

NPI Number	1306613823
Provider Enumeration Date	12/05/2023
Last Update Date	12/05/2023
Certification Date	12/05/2023

Medical Identifiers

Medical identifiers for Impactherapeutics such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1306613823	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
251S00000X	Community/behavioral Health	(* (Not Available))	Primary

News Archive

Negative stress increases risk for coronary heart disease in cancer patient's relatives

A current study shows that the risk for coronary heart disease and stroke increases by almost thirty per cent in a person whose partner has cancer. The cause is probably the negative stress to which the cancer patient's relative is exposed.

Study highlights potential benefit of follow-up screening for woman with early breast cancer

Public health researchers from the University of Adelaide have evaluated international breast cancer guidelines, finding that there is potential to improve surveillance of breast cancer survivors from both a patient and health system perspective.

Biomedical scientist receives $1.83 million NIH grant for inflammatory bowel disease research

A biomedical scientist at the University of California, Riverside has received a $1.83 million grant to identify how the loss of a protective barrier in the intestine contributes to inflammatory bowel disease (IBD).

HealthSouth announces credit agreement amendment and extended maturity of a portion of its term loan

HealthSouth Corporation today announced it has amended its credit agreement and extended maturity of a portion of its term loan. A segment of the lenders under the term loan that has a current outstanding balance of approximately $750 million will extend the maturity for $300 million of that loan from March 2013 to September 2015, contingent on certain conditions.

KYTHERA ATX-101-10-16 trial for submental fat meets primary endpoints

KYTHERA Biopharmaceuticals, Inc. today announced the presentation of initial trial results from Study ATX-101-10-16, the first of two pivotal European Phase III clinical trials with ATX-101, a facial injectable drug for the reduction of unwanted fat under the chin, or submental fat.

Impactherapeutics - Mental Health Clinic in Andover, OH